About Kymera Therapeutics, Inc.
https://www.kymeratx.comKymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system.
CEO
Nello Mainolfi
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 152
Ratings Snapshot
Rating : C-
Most Recent Analyst Grades
B. Riley Securities
Buy
Jefferies
Buy
B of A Securities
Buy
BTIG
Buy
Citigroup
Buy
HC Wainwright & Co.
Buy
Grade Summary
Showing Top 6 of 19
Price Target
Institutional Ownership
BAKER BROS. ADVISORS LP
Shares:6.65M
Value:$500.25M
AVORO CAPITAL ADVISORS LLC
Shares:6.35M
Value:$477.58M
FMR LLC
Shares:5.88M
Value:$442.21M
Summary
Showing Top 3 of 231
About Kymera Therapeutics, Inc.
https://www.kymeratx.comKymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $2.76M ▼ | $21.19M ▼ | $-82.17M ▼ | -2.97K% ▼ | $-0.94 ▲ | $-79.33M ▼ |
| Q2-2025 | $11.48M ▼ | $93.95M ▼ | $-76.61M ▼ | -667.6% ▼ | $-0.95 ▼ | $-74.42M ▼ |
| Q1-2025 | $22.1M ▲ | $96.53M ▲ | $-65.58M ▲ | -296.75% ▲ | $-0.82 ▲ | $-63.46M ▲ |
| Q4-2024 | $7.39M ▲ | $88.15M ▲ | $-70.75M ▼ | -956.88% ▲ | $-0.88 ▼ | $-68.71M ▼ |
| Q3-2024 | $3.74M | $75.86M | $-62.49M | -1.67K% | $-0.82 | $-60.44M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $505.68M ▼ | $1.1B ▼ | $155.79M ▼ | $946.26M ▼ |
| Q2-2025 | $665.45M ▲ | $1.13B ▲ | $159.59M ▲ | $971.48M ▲ |
| Q1-2025 | $463.15M ▼ | $918.31M ▼ | $132.08M ▼ | $786.23M ▼ |
| Q4-2024 | $488.74M ▼ | $978.03M ▼ | $142.42M ▲ | $835.62M ▼ |
| Q3-2024 | $549.97M | $1.03B | $141.91M | $892.93M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-82.17M ▼ | $-27.11M ▲ | $-235.3M ▼ | $39.51M ▼ | $-222.9M ▼ | $-27.29M ▲ |
| Q2-2025 | $-76.61M ▼ | $-59.88M ▲ | $60.02M ▲ | $245.73M ▲ | $245.86M ▲ | $-60.58M ▲ |
| Q1-2025 | $-65.58M ▲ | $-79.15M ▼ | $48.62M ▼ | $258K ▼ | $-30.28M ▼ | $-79.62M ▼ |
| Q4-2024 | $-70.75M ▼ | $-61.78M ▼ | $68.57M ▲ | $2.77M ▼ | $9.55M ▼ | $-62.72M ▼ |
| Q3-2024 | $-62.49M | $-50.19M | $-157.68M | $250.92M | $43.05M | $-50M |
CEO
Nello Mainolfi
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 152
Ratings Snapshot
Rating : C-
Most Recent Analyst Grades
B. Riley Securities
Buy
Jefferies
Buy
B of A Securities
Buy
BTIG
Buy
Citigroup
Buy
HC Wainwright & Co.
Buy
Grade Summary
Showing Top 6 of 19
Price Target
Institutional Ownership
BAKER BROS. ADVISORS LP
Shares:6.65M
Value:$500.25M
AVORO CAPITAL ADVISORS LLC
Shares:6.35M
Value:$477.58M
FMR LLC
Shares:5.88M
Value:$442.21M
Summary
Showing Top 3 of 231